FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

| OMB APPROVAL        |           |  |  |  |  |  |  |  |  |  |
|---------------------|-----------|--|--|--|--|--|--|--|--|--|
| OMB Number:         | 3235-0287 |  |  |  |  |  |  |  |  |  |
| Estimated average b | ourden    |  |  |  |  |  |  |  |  |  |

0.5

hours per response:

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

| Name and Address of Reporting Person* <u>Krognes Steve E.</u>   |  |   |  | 2.                           | Issuer Name and Ticker or Trading Symbol     Denali Therapeutics Inc. [ DNLI ] |  |      |  |  |   |                 |                                    | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director 10% Owner  Officer (give title Other (specify |  |   |   |   |  |
|---|--|---|--|------------------------------|--|--|------|--|--|---|-----------------|------------------------------------|---|--|---|---|---|--|
| (Last) (First) (Middle) C/O DENALI THERAPEUTICS INC. 161 OYSTER POINT BLVD.   |  |   |  |                              | 3. Date of Earliest Transaction (Month/Day/Year) 02/10/2020                    |  |      |  |  |   |                 |                                    | X Office (give title Office (specify below)  CFO and Treasurer  |  |   |   |   |  |
| (Street) SOUTH SAN FRANCISCO CA 94080  (City) (State) (Zip)  4. If Amendment, Date of Original Filed (Month/Day/Year) |  |   |  |                              |  |  | Li   | ine)<br>X  | ′  |   |                 |                                    |   |  |   |   |   |  |
| Table I - Non-Deriva  1. Title of Security (Instr. 3)  2. Transa Date (Month/D  |  |   |  | ransactio                    | action 2A. Deemed Execution Date,  |  |      | 3.<br>Transacti  | Transaction Disposed Of (D) (Ir Code (Instr. |   |                 | ired (A) or                        |   | 5. Amoun<br>Securities<br>Beneficia<br>Owned Fo                              | s<br>ally<br>ollowing                       | 6. Ownership<br>Form: Direct<br>(D) or Indirect<br>(I) (Instr. 4) | : Direct   I<br>Indirect   E<br>str. 4)   C | 7. Nature of Indirect Beneficial Ownership |
|   |  |   |  |                              |  |  | Code |  | Amount (A                                    |   | Price           |                                    | Reported<br>Transacti<br>(Instr. 3 a  | ion(s)   |   |   | (Instr. 4)                                  |  |
|   | Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) |   |  |                              |  |  |      |  |  |   |                 |                                    |   |  |   |   |   |  |
| 1. Title of<br>Derivative<br>Security<br>(Instr. 3)   | 2.<br>Conversion<br>or Exercise<br>Price of<br>Derivative<br>Security  | ersion Date Execution Date, if any (Month/Day/Year) of (Month/Day/Year) |  | 4.<br>Transa<br>Code (<br>8) |  | 5. Number of<br>Derivative<br>Securities<br>Acquired (A)<br>or Disposed<br>of (D) (Instr.<br>3, 4 and 5) |      | 6. Date Exercisable and<br>Expiration Date<br>(Month/Day/Year) |  | 7. Title and Amou<br>of Securities<br>Underlying<br>Derivative Securi<br>(Instr. 3 and 4) |                 | Derivative<br>Security             |   | 9. Number derivative Securities Beneficia Owned Following Reported Transacti | Owners Form: Direct (I or Indire (I) (Instr | Ownership   | Beneficial<br>Ownership<br>(Instr. 4)       |  |
|   |  |   |  | Code                         | v  | (A)  | (D)  | Date<br>Exercisable  | Expi<br>Date                                 | iration<br>e  | Title           | Amount<br>or<br>Number<br>of Share | .   |  | (Instr. 4)                                  | on(s)   |   |  |
| Restricted<br>Stock<br>Units  | (1)  | 02/10/2020  |  | A                            |  | 29,143   |      | (2)  |  | (2)   | Common<br>Stock | 29,14                              | 3   | \$0.00   | 29,14                                       | 3   | D   |  |
| Stock<br>Option<br>(right to<br>buy)  | \$24.81  | 02/10/2020  |  | A                            |  | 136,000  |      | (3)  | 02/0   | 09/2030   | Common<br>Stock | 136,00                             | 00  | \$0.00   | 136,00                                      | 00  | D   |  |

## ${\bf Explanation\ of\ Responses:}$

- 1. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer.
- 2. 25% of the restricted stock units shall vest on February 10, 2021 (the "Vesting Commencement Date") and an additional 25% of the restricted stock units shall vest on each annual anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date.
- 3. 25% of the shares subject to the option shall vest on February 10, 2021, and 1/48 of the shares subject to the option shall vest each month thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date.

## Remarks:

/s/ Tyler Nielsen, by power of attorney

02/12/2020

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.